Isobologram analysis was used to examine the interaction between 1-fiD-arabinofuranosylcytosine (Ara-C), thymidine (dThd), and hydroxyurea. All three pairs of drugs, as well as the triple combination, were synergistic against a human B cell line in vitro across a broad range of concentrations. Synergy was associated with an increase in the Ara-C nucleotide pool and Ara-C triphosphate concentration. dThd increased, and hydroxyurea decreased, the incorporation ofAra-C into trichloroacetic acid-insoluble macromolecules per unit time. Hydroxyurea was more effective than dThd at equimolar concentrations in increasing the acid-soluble Ara-C pool. Maximal stimulation of Ara-C triphosphate formation by dThd occurred at 1 mM and was associated with reduction of the deoxycytidine triphosphate pool to 31% of control. At the same concentration, hydroxyurea increased Ara-C triphosphate formation to a greater extent but increased deoxycytidine triphosphate to 116% of control. When tested at clinically achievable concentrations on blasts from patients with acute leukemia, hydroxyurea increased the Ara-C nucleotide pool in all six cases studied, whereas dThd decreased the Ara-C nucleotide pool. These results indicate that in SB cells dThd and hydroxyurea work by different mechanisms to augment the Ara-C nucleotide pool and that hydroxyurea may be more effective than dThd as a modulator of Ara-C activity in patients with acute leukemia.1-3-D-Arabinofuranosylcytosine (Ara-C) is one of the most important drugs in the treatment of human acute leukemia (1-4). A significant increase in the selectivity of Ara-C may have farreaching consequences for the management ofthis disease. Ara-C behaves as an analog of deoxycytidine (dCyd) that, when phosphorylated to 1-,3-D-arabinofuranosylcytosine triphosphate (Ara-CTP), is a potent inhibitor of DNA polymerase (5-7) and is also incorporated into DNA (7-9). The activity of Ara-C is determined by the amount of Ara-CTP formed within the cell, and the concentration of the natural substrate deoxycytidine triphosphate (dCTP), with which Ara-CTP must compete for binding to DNA polymerase (5, 6, 10, 11).Phosphorylation of Ara-C is normally constrained by feedback inhibition ofdCTP on dCyd kinase, the enzyme catalyzing the rate-limiting step in the dCyd salvage pathway (12, 13). Thymidine (dThd) has been shown to increase the toxicity of Ara-C in vitro and in vivo against several murine (14-17) and human tumors (16). This is in part due to the ability ofthymidine triphosphate (dTTP) to inhibit ribonucleotide reductase (18), which catalyzes an obligatory step in the die novo synthesis of dCTP (19,20) and depletes the cellular dCTP pool (15,18,19,(21)(22)(23)(24)(25)(26). Hydroxyurea (HU) is also an inhibitor of mammalian ribonucleotide reductase (27), but one that binds at a different site than dTTP (28,29). HU has also been demonstrated to enhance the phosphorylation of Ara-C in murine cells (12,(30)(31)(32) and to markedly improve the therapeutic ratio ofAra-C against the murine L1210 leukemi...
The effect of thymidine (dThd) and hydroxyurea (HU) on the cellular metabolism of 1-beta-D-arabinofuranosylcytosine (Ara-C) was investigated in the human promyelocytic cell line HL-60. Both dThd and HU increased the cellular uptake and rate of formation of Ara-CTP. Measurement of ribo- and deoxyribonucleotide triphosphate pools implicated a reduction of the dCTP as the mechanism of this effect. dThd and HU had opposite effects on the incorporation of Ara-C into DNA per unit time, but both enhanced the incorporation of Ara-C per unit of newly synthesized DNA. In a Phase I trial Ara-C was given by continuous infusion for five days at 100 mg/m2, and HU by mouth every six hours with dose escalation from 0.375 to 1.78 g/m2 every six hours. Myelosuppression was the dose-limiting toxicity; the major nonhematologic toxicity was skin rash. To date responses have been observed in chronic myelogenous leukemia in blast crisis and diffuse histiocytic lymphoma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.